- Home
- LSB vs GNLX Comparison
LSB vs GNLX Comparison
Compare LSB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- GNLX
- Stock Information
- Founded
- LSB 2002
- GNLX 2001
- Country
- LSB China
- GNLX United States
- Employees
- LSB N/A
- GNLX N/A
- Industry
- LSB
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- GNLX Health Care
- Exchange
- LSB NYSE
- GNLX Nasdaq
- Market Cap
- LSB 49.8M
- GNLX 103.6M
- IPO Year
- LSB N/A
- GNLX 2023
- Fundamental
- Price
- LSB $3.64
- GNLX $2.41
- Analyst Decision
- LSB
- GNLX Strong Buy
- Analyst Count
- LSB 0
- GNLX 4
- Target Price
- LSB N/A
- GNLX $18.25
- AVG Volume (30 Days)
- LSB 23.5K
- GNLX 116.5K
- Earning Date
- LSB 01-21-2025
- GNLX 11-14-2024
- Dividend Yield
- LSB N/A
- GNLX N/A
- EPS Growth
- LSB N/A
- GNLX N/A
- EPS
- LSB N/A
- GNLX N/A
- Revenue
- LSB $79,415,311.00
- GNLX $8,000.00
- Revenue This Year
- LSB $39.33
- GNLX N/A
- Revenue Next Year
- LSB $75.61
- GNLX N/A
- P/E Ratio
- LSB N/A
- GNLX N/A
- Revenue Growth
- LSB N/A
- GNLX N/A
- 52 Week Low
- LSB $1.88
- GNLX $1.60
- 52 Week High
- LSB $11.20
- GNLX $16.36
- Technical
- Relative Strength Index (RSI)
- LSB 58.78
- GNLX 44.83
- Support Level
- LSB $2.10
- GNLX $2.13
- Resistance Level
- LSB $3.70
- GNLX $2.53
- Average True Range (ATR)
- LSB 0.39
- GNLX 0.16
- MACD
- LSB 0.10
- GNLX 0.01
- Stochastic Oscillator
- LSB 73.93
- GNLX 39.55
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.